About Norgine
Norgine is a Healthcare company based in Amsterdam (Netherlands) founded in 1906, and was acquired by Goldman Sachs in May 2022. It operates as a proprietary therapeutic products for gastrointestinal diseases are developed and marketed. Norgine has completed 3 acquisitions, including Azanta, Merus Labs and Theravia. Its focus areas include Life Sciences, Gastroenterology, Drugs and Diversified. Its competitors include Ironwood Pharma, RedHill Biopharma, Alcresta, Seed and Ardelyx and 4 more; 6 of its 9 listed competitors have raised funding.
Company details
Norgine was founded in 1906 and is headquartered in Amsterdam, Netherlands. Operations in the pharmaceutical sector are centered on the development and marketing of therapeutic products, with primary emphasis on gastrointestinal diseases and additional involvement in hepatology and critical care. A portfolio of 9 products generated EUR 300M in revenue during 2015. Seven pipeline candidates are under development, including five for gastroenterology and two for critical care.
- Headquarters Amsterdam, Netherlands
- Stage Acquired
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website norgine.com
- Social LinkedIn X YouTube
- Acquired by Goldman Sachs (May 2022)
- Investors
- Investments & AcquisitionsAzanta
& 2 more
- Acquired byGoldman Sachs
(May 2022)
Apps and channels of Norgine
its YouTube channel Norgine has 54 subscribers and 18 videos.
Videos from Norgine
The most watched videos on Norgine's YouTube channel, Norgine (54 subscribers). Click a video to play it here.
More on Norgine.
Investors in Norgine
Norgine has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Goldman Sachs.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investment banking services are delivered across multiple financial sectors. | 1869 | goldmansachs.com | New York, United States |
Investor details for Norgine
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Norgine
169 people are tracked at Norgine (72 in leadership, 97 in team).
| Name | Role | Group |
|---|---|---|
Bethan Gingell | Associate Quality Director | Leadership |
David Strickland | Learning And Capability Director | Leadership |
Suzi Archer | People Engagement Director | Leadership |
Sheila Hopkins | Chief Legal Officer | Leadership |
Wendy Logan | VP, Business Unit Head | Leadership |
Isidore Duru | Head Of Commercial, Specialty Care Rx Portfolio, UK And Ireland | Leadership |
Alan Butcher | Chief Corporate Development Officer | Leadership |
David Gillen | Chief Medical Officer | Leadership |
Darna Comal | Regional Vice President Of Sales | Leadership |
Christopher Bath | CEO | Leadership |
Raj Daruvala | VP, Transformation Management | Leadership |
Ina Helle | Nordic Head Of Commercial, Speciality RX | Leadership |
Tracy James | VP Marketing Consumer Healthcare | Leadership |
Jonathan Hammond | Vice President Technical Operations | Leadership |
Ramya Devanand | Head Of Commercial Evaluation, Business And Corporate Development | Leadership |
Marianne Cureau | HR Director Commercial And Business Development | Leadership |
Jo Pillai | VP Human Resources | Leadership |
Lena Henning | Head Of HR Nordics | Leadership |
Andreas Wöller | Director Legal Services | Leadership |
Cécile Amigues | Senior Director Of Legal Services | Leadership |
149 more people are available in the full profile.
Complete people profiles for Norgine
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Norgine
Norgine has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include Azanta, Merus Labs and Theravia.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Therapies for rare and neglected diseases are developed and promoted. | theravia.com | – | 0 | Apr 2025 | •••• | |
Medicines for orphan oncology and women's health devices are developed. | azanta.com | Copenhagen, Denmark | 1994 | Mar 2020 | •••• | |
Pharmaceuticals for women's health, cancer, infectious and cardiovascular disease. | meruslabs.com | Toronto, Canada | 2009 | May 2017 | $264.88M |
Complete acquisition details for Norgine
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Norgine
5 dated milestones of Norgine across 119 years, from founding to its latest funding, stage changes and deals.
- Founded Norgine is founded.
- Acquisition Acquires Merus Labs.
- Acquisition Acquires Azanta.
- Exit Acquired by Goldman Sachs.
- Acquisition Acquires Theravia.
Competitors of Norgine
Norgine has 9 listed competitors in our database, 6 of them funded. They include Ironwood Pharma, RedHill Biopharma, Alcresta, Seed and Ardelyx, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| ironwoodpharma.com | 1998 | Cambridge, United States | $206.25M | 220 | Therapeutics for gastrointestinal disorders, including linaclotide, are developed. | |
| redhillbio.com | 2009 | Ramat Gan, Israel | $13.5M | 183 | Developer of therapeutics for the treatment of gastrointestinal and infectious diseases | |
| alcresta.com | 2011 | Newton, United States | $95.89M | 52 | Enzyme-based products for gastrointestinal disorders are developed using immobilization technology. | |
| seed.com | 2016 | Los Angeles, United States | $40.62M | – | Synbiotics are developed for simulating the gut microbiome. | |
| ardelyx.com | 2007 | Fremont, United States | $61.1M | 37 | Therapeutics for gastrointestinal, cardio-renal, and metabolic diseases are developed. | |
| bauschhealth.com | 1960 | Laval, Canada | – | 808 | Therapeutics for multiple diseases including dermatology and neurology are developed. | |
| cosmopharma.com | 1996 | Dublin, Ireland | – | – | Therapeutics for gastrointestinal diseases are developed and provided. | |
| lianbio.com | 1999 | Shanghai, China | – | – | Therapeutics for cardiorenal and oncology diseases are developed. | |
| onconic.co.kr | 2020 | Seoul, South Korea | $19.9M | – | Therapeutics for cancer and gastrointestinal diseases are developed. |
Detailed competitors of Norgine
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Norgine
The website of Norgine (norgine.com) receives about 5.1K visits a month and ranks #3,953,272 among all websites worldwide, #4,990 in Biotechnology and Pharmaceuticals.
- Monthly visits5.1K
▲ 10.2% vs previous month
- Unique visitors1.9K
per month
- Global rank#3,953,272
among all websites
- Category rank#4,990
Health · Biotechnology and Pharmaceuticals
- Bounce rate42%
- Pages per visit1.8
- Average visit10 sec
- DevicesDesktop 40% · Mobile 60%
Websites whose visitors overlap most with Norgine. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
pfizer.be | pfizer.be | 100% | – | #1,564,584 | – |
takeda.co.uk | takeda.co.uk | 100% | – | – | – |
allergan.co.uk | allergan.co.uk | 100% | – | – | – |
| smblab.be | 100% | – | – | View details | |
| merck.com | 100% | 656.8K | #78,842 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 15 similar websites and full traffic analytics for Norgine
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 15 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Gastroenterology
10 companies that operate in the same segment as Norgine (Gastroenterology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for gastrointestinal disorders, including linaclotide, are developed. | 1998 | Cambridge, Massachusetts, United States | USD 206.25 M | USD 296.15 M | 253 | |
Implantable battery-powered pumps for ascites removal are developed. | 2006 | Zurich, Switzerland | USD 35.5 M | – | – | |
Sacral neuromodulation devices are developed for urinary and bowel control. | 2013 | Irvine, California, United States | USD 143.47 M | – | – | |
Provider of a deep learning platform for detecting circulating cancer-related markers | 2014 | United States | USD 1.35 B | – | 411 | |
Developer of electrosurgical system and range of flexible endoscopic instruments | 2003 | Chepstow, Monmouthshire, United Kingdom | USD 20.84 M | USD 8.08 M | 141 | |
Non-invasive biomarker tests for colorectal cancer are developed. | 2015 | St. Louis, Missouri, United States | USD 218.95 M | – | – | |
Pendulum is focused on developing advanced probiotic solutions. | 2012 | San Francisco, California, United States | USD 109.5 M | – | 55 | |
Therapeutics for gastrointestinal, cardio-renal, and metabolic diseases are developed. | 2007 | Fremont, California, United States | USD 61.1 M | USD 407.32 M | 395 | |
Developer of therapeutics for the treatment of gastrointestinal and infectious diseases | 2009 | Ramat Gan, Tel Aviv District, Israel | USD 13.5 M | USD 288.27 K | 35 | |
Biologics are developed for cardio-metabolic and liver diseases. | 2007 | San Francisco, California, United States | USD 358.87 M | USD 330.53 M | 71 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Norgine
Complete news archive for Norgine
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Norgine
Norgine was founded in 1906.
Norgine is headquartered in Amsterdam, Netherlands.
Norgine was founded in 1906 and is headquartered in Amsterdam, Netherlands. Operations in the pharmaceutical sector are centered on the development and marketing of therapeutic products, with primary emphasis on gastrointestinal diseases and additional involvement in hepatology and critical care. A portfolio of 9 products generated EUR 300M in revenue during 2015. Seven pipeline candidates are under development, including five for gastroenterology and two for critical care.
Norgine's top competitors include Ironwood Pharma, Ardelyx and RedHill Biopharma.
Norgine has made 3 acquisitions, including Azanta, Merus Labs, and Theravia.
Norgine has 1 investor. Key investors include Goldman Sachs.
Yes. Norgine was acquired by Goldman Sachs in May 2022.